Free Trial

Triglav Skladi D.O.O. Acquires New Shares in ResMed Inc. (NYSE:RMD)

ResMed logo with Medical background

Triglav Skladi D.O.O. purchased a new position in shares of ResMed Inc. (NYSE:RMD - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 7,400 shares of the medical equipment provider's stock, valued at approximately $1,692,000.

Other large investors have also recently bought and sold shares of the company. Howard Capital Management Inc. boosted its holdings in shares of ResMed by 5.3% in the 4th quarter. Howard Capital Management Inc. now owns 900 shares of the medical equipment provider's stock valued at $206,000 after buying an additional 45 shares during the last quarter. Faithward Advisors LLC boosted its holdings in shares of ResMed by 4.3% in the 4th quarter. Faithward Advisors LLC now owns 1,279 shares of the medical equipment provider's stock valued at $292,000 after buying an additional 53 shares during the last quarter. Meiji Yasuda Life Insurance Co boosted its holdings in shares of ResMed by 4.6% in the 4th quarter. Meiji Yasuda Life Insurance Co now owns 1,356 shares of the medical equipment provider's stock valued at $310,000 after buying an additional 60 shares during the last quarter. HighPoint Advisor Group LLC boosted its holdings in shares of ResMed by 2.6% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,570 shares of the medical equipment provider's stock valued at $610,000 after buying an additional 64 shares during the last quarter. Finally, Brooklyn Investment Group boosted its holdings in shares of ResMed by 8.1% in the 4th quarter. Brooklyn Investment Group now owns 911 shares of the medical equipment provider's stock valued at $208,000 after buying an additional 68 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company's stock.

ResMed Stock Performance

RMD stock traded down $2.46 during trading hours on Friday, hitting $243.03. 558,144 shares of the stock were exchanged, compared to its average volume of 1,021,518. The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $35.63 billion, a P/E ratio of 28.69, a P/E/G ratio of 1.53 and a beta of 0.78. The company has a 50-day simple moving average of $227.88 and a two-hundred day simple moving average of $234.34. ResMed Inc. has a 12 month low of $179.42 and a 12 month high of $263.05.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.01. The firm had revenue of $1.29 billion for the quarter, compared to analysts' expectations of $1.28 billion. ResMed had a return on equity of 26.17% and a net margin of 25.34%. The company's quarterly revenue was up 7.9% compared to the same quarter last year. During the same quarter last year, the business earned $2.13 EPS. On average, analysts forecast that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 12th. Shareholders of record on Thursday, May 8th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 0.87%. The ex-dividend date is Thursday, May 8th. ResMed's payout ratio is 23.79%.

Insiders Place Their Bets

In related news, CEO Michael J. Farrell sold 8,009 shares of the firm's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $229.20, for a total value of $1,835,662.80. Following the transaction, the chief executive officer now owns 455,472 shares in the company, valued at approximately $104,394,182.40. This trade represents a 1.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kaushik Ghoshal sold 9,113 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $235.40, for a total value of $2,145,200.20. Following the completion of the transaction, the insider now owns 9,725 shares in the company, valued at $2,289,265. The trade was a 48.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,949 shares of company stock worth $11,822,260 in the last 90 days. Company insiders own 0.71% of the company's stock.

Wall Street Analyst Weigh In

RMD has been the subject of several recent analyst reports. Needham & Company LLC reissued a "hold" rating on shares of ResMed in a report on Friday, January 31st. Citigroup raised ResMed from a "neutral" rating to a "buy" rating in a report on Wednesday, March 5th. Royal Bank of Canada increased their price objective on ResMed from $247.00 to $255.00 and gave the company a "sector perform" rating in a report on Thursday, April 24th. JPMorgan Chase & Co. increased their price target on ResMed from $286.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, April 24th. Finally, Mizuho set a $265.00 price target on ResMed in a research note on Wednesday, April 16th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, ResMed presently has a consensus rating of "Moderate Buy" and an average target price of $259.33.

Get Our Latest Analysis on ResMed

About ResMed

(Free Report)

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.

Further Reading

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Should You Invest $1,000 in ResMed Right Now?

Before you consider ResMed, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ResMed wasn't on the list.

While ResMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA
This Unique Robotaxi Play Could Deliver 10X Returns

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines